INR 310.45
(-0.34%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 204.07 Million INR | -51.01% |
2022 | 416.56 Million INR | 26.81% |
2021 | 328.5 Million INR | 14.48% |
2020 | 286.93 Million INR | 7.42% |
2019 | 267.12 Million INR | 23.58% |
2018 | 216.15 Million INR | 30.45% |
2017 | 165.69 Million INR | 14.0% |
2016 | 145.35 Million INR | 8.66% |
2015 | 133.76 Million INR | 8.06% |
2014 | 123.78 Million INR | 14.81% |
2013 | 107.82 Million INR | 36.33% |
2012 | 79.08 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 29.24 Million INR | -2.63% |
2024 Q1 | 30.02 Million INR | 51.9% |
2023 Q1 | 133.11 Million INR | -4.57% |
2023 Q2 | 120.75 Million INR | -9.28% |
2023 FY | 75 Million INR | -81.99% |
2023 Q4 | 19.76 Million INR | -33.81% |
2023 Q3 | 29.86 Million INR | -75.27% |
2022 Q2 | 88.06 Million INR | 7.42% |
2022 Q4 | 139.48 Million INR | 30.32% |
2022 FY | 416.56 Million INR | 26.81% |
2022 Q1 | 81.97 Million INR | -10.24% |
2022 Q3 | 107.03 Million INR | 21.55% |
2021 Q2 | 65.8 Million INR | -22.78% |
2021 Q1 | 85.21 Million INR | -16.96% |
2021 FY | 328.5 Million INR | 14.48% |
2021 Q4 | 91.32 Million INR | 6.02% |
2021 Q3 | 86.14 Million INR | 30.9% |
2020 Q1 | 58.29 Million INR | -9.11% |
2020 FY | 286.93 Million INR | 7.42% |
2020 Q4 | 102.62 Million INR | 63.33% |
2020 Q3 | 62.83 Million INR | -0.53% |
2020 Q2 | 63.16 Million INR | 8.36% |
2019 Q3 | 65.19 Million INR | -18.44% |
2019 Q1 | 57.86 Million INR | -8.08% |
2019 FY | 267.12 Million INR | 23.58% |
2019 Q2 | 79.93 Million INR | 38.15% |
2019 Q4 | 64.13 Million INR | -1.61% |
2018 Q3 | 64.95 Million INR | 38.07% |
2018 Q4 | 62.95 Million INR | -3.09% |
2018 FY | 216.15 Million INR | 30.45% |
2018 Q1 | 41.2 Million INR | 0.0% |
2018 Q2 | 47.04 Million INR | 14.18% |
2017 FY | 165.69 Million INR | 14.0% |
2016 FY | 145.35 Million INR | 8.66% |
2016 Q4 | 78.56 Million INR | 0.0% |
2015 Q2 | 32.08 Million INR | 0.0% |
2015 Q3 | 36.63 Million INR | 14.2% |
2015 Q4 | 68.83 Million INR | 87.87% |
2015 FY | 133.76 Million INR | 8.06% |
2015 Q1 | 32.08 Million INR | -0.16% |
2014 FY | 123.78 Million INR | 14.81% |
2014 Q4 | 32.13 Million INR | 0.0% |
2013 FY | 107.82 Million INR | 36.33% |
2012 FY | 79.08 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sigachi Industries Limited | 579.88 Million INR | 64.807% |
Ind-Swift Limited | 946.56 Million INR | 78.44% |
Bajaj HealthCare Limited | 985.34 Million INR | 79.289% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.633% |
Innova Captab Limited | 931.03 Million INR | 78.08% |
Divi's Laboratories Limited | 14.17 Billion INR | 98.56% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 91.749% |
Morepen Laboratories Limited | 1.98 Billion INR | 89.732% |
Mankind Pharma Limited | 29.27 Billion INR | 99.303% |
Sequent Scientific Limited | 2.9 Billion INR | 92.967% |
Wanbury Limited | 978.96 Million INR | 79.154% |
Laurus Labs Limited | 11.9 Billion INR | 98.286% |
Nectar Lifesciences Limited | 932.7 Million INR | 78.12% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 98.247% |
Alembic Limited | 872.45 Million INR | 76.609% |
Hikal Limited | 4.46 Billion INR | 95.428% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 98.714% |
Neuland Laboratories Limited | 2.92 Billion INR | 93.034% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 98.62% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.565% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 90.728% |
Themis Medicare Limited | 1.12 Billion INR | 81.873% |
RPG Life Sciences Limited | 1.63 Billion INR | 87.522% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.837% |
Lupin Limited | 125.09 Billion INR | 99.837% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 90.254% |
Wockhardt Limited | 8.48 Billion INR | 97.593% |
Vaishali Pharma Limited | 84.02 Million INR | -142.867% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 93.362% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 53.465% |
Jubilant Pharmova Limited | 14.45 Billion INR | 98.588% |
FDC Limited | 3.49 Billion INR | 94.169% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.787% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 50.518% |
Eris Lifesciences Limited | 4.94 Billion INR | 95.871% |
Venus Remedies Limited | 1.91 Billion INR | 89.35% |
ZIM Laboratories Limited | 1.01 Billion INR | 79.855% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 85.62% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -250.122% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 90.615% |
Shilpa Medicare Limited | 3.33 Billion INR | 93.879% |
Albert David Limited | 1.02 Billion INR | 80.112% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.33% |
Hester Biosciences Limited | 908.84 Million INR | 77.545% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 85.452% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 92.01% |
Gufic Biosciences Limited | 1.18 Billion INR | 82.801% |
Windlas Biotech Limited | 1 Billion INR | 79.724% |
Procter & Gamble Health Limited | 2.99 Billion INR | 93.187% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -1335.862% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -25.798% |
Granules India Limited | 10.31 Billion INR | 98.021% |
Aarti Drugs Limited | 1.16 Billion INR | 82.52% |
Bal Pharma Limited | 555.62 Million INR | 63.27% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.378% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.868% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 81.002% |
Medicamen Biotech Limited | 335.16 Million INR | 39.111% |
Unichem Laboratories Limited | 6.72 Billion INR | 96.966% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 55.205% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -2892.361% |
Valiant Laboratories Limited | 138.02 Million INR | -47.852% |
Orchid Pharma Limited | 800.77 Million INR | 74.515% |
Medico Remedies Limited | 59.67 Million INR | -241.984% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 90.393% |
Ipca Laboratories Limited | 18.98 Billion INR | 98.925% |
Brooks Laboratories Limited | 51.18 Million INR | -298.748% |
Syncom Formulations (India) Limited | 345.63 Million INR | 40.955% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.679% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.047% |
NATCO Pharma Limited | 10.05 Billion INR | 97.971% |
Suven Life Sciences Limited | 109.75 Million INR | -85.949% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -342.151% |
Strides Pharma Science Limited | 9.16 Billion INR | 97.773% |
Indoco Remedies Limited | 12.06 Billion INR | 98.308% |
Alpa Laboratories Limited | 127.38 Million INR | -60.213% |
Lasa Supergenerics Limited | 291.17 Million INR | 29.912% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 93.367% |